NuVasive (NuVasive) Cash, Cash Equivalents, Marketable Securities : $81 Mil (As of Jun. 2023)

View and export this data going back to 2004. Start your Free Trial

What is NuVasive Cash, Cash Equivalents, Marketable Securities?

NuVasive's quarterly cash, cash equivalents, marketable securities declined from Dec. 2022 ($248.66 Mil) to Mar. 2023 ($181.20 Mil) but then stayed the same from Mar. 2023 ($181.20 Mil) to Jun. 2023 ($80.72 Mil).

NuVasive's annual cash, cash equivalents, marketable securities declined from Dec. 2020 ($1,030.01 Mil) to Dec. 2021 ($246.09 Mil) but then increased from Dec. 2021 ($246.09 Mil) to Dec. 2022 ($248.66 Mil).

NuVasive Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for NuVasive's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NuVasive Cash, Cash Equivalents, Marketable Securities Chart

NuVasive Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

117.84

213.03

1,030.01

246.09

248.66

NuVasive Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															225.99	237.50	248.66	181.20	80.72

NuVasive Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

NuVasive (NAS:NUVA) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

NuVasive Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of NuVasive's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

NuVasive (NuVasive) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NuVasive Inc (NAS:NUVA) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

12101 Airport Way, Broomfield, CO, USA, 92121

Website

https://www.nuvasive.com

NuVasive Inc is a medical technology company focused on developing, manufacturing, selling and providing procedural solutions for spine surgery, with a guiding purpose to transform surgery, advance care and change lives. The company has a portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring. It also develop and sell magnetically adjustable implant systems for spine and specialized orthopedic procedures.

Executives

Michael Farrington	officer: SVP, People and Culture	7475 LUSK BLVD., SAN DIEGO CA 92121
Marc W. Rosenbaum	officer: Chief Accounting Officer	7475 LUSK BLVD., SAN DIEGO CA 92121
James Christopher Barry	director, officer: Chief Executive Officer	7475 LUSK BLVD, SAN DIEGO CA 92121
Andrew C. Morton	officer: SVP, CHRO	10910 DOMAIN DRIVE, SUITE 300, AUSTIN TX 78758
Amy Belt Raimundo	director	ONE KAISER PLAZA, 22ND FLOOR, OAKLAND CA 94612
Lucas Vitale	officer: Chief Human Resources Officer	7475 LUSK BLVD, SAN DIEGO CA 92121
Massimo Calafiore	officer: EVP, Global Business Units	7475 LUSK BLVD., SAN DIEGO CA 92121
Siddhartha Kadia	director	7475 LUSK BOULEVARD, SAN DIEGO CA 92121
Vickie L Capps	director	2985 SCOTT STREET, VISTA CA 92083
Brent J. Boucher	officer: EVP, Global Commercial	14 PLAZA DRIVE, LATHAM NY 12110
Matthew Link	officer: Exec. VP U.S. Sales	7475 LUSK BLVD, SAN DIEGO CA 92121
Matthew K Harbaugh	officer: EVP and CFO	675 MCDONNELL BLVD., HAZELWOOD MO 63042
Dale A. Wolf	officer: SVP, Global Operations	7475 LUSK BLVD., SAN DIEGO CA 92121
Gregory T Lucier	director	C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Paul Mcclintock	officer: President, U.S. Commercial	7475 LUSK BLVD, SAN DIEGO CA 92121